PMID- 21885622
OWN - NLM
STAT- MEDLINE
DCOM- 20111026
LR  - 20151119
IS  - 1552-5783 (Electronic)
IS  - 0146-0404 (Linking)
VI  - 52
IP  - 9
DP  - 2011 Sep 1
TI  - Preferential hyperacuity perimeter as a functional tool for monitoring exudative 
      age-related macular degeneration in patients treated by intravitreal ranibizumab.
PG  - 7012-8
LID - 10.1167/iovs.11-7517 [doi]
AB  - PURPOSE: To analyze the response to anti vascular endothelial growth factor 
      (VEGF) treatment for exudative age-related macular degeneration (AMD), with 
      respect to changes in the Preferential Hyperacuity Perimeter (PHP), 
      best-corrected visual acuity (BCVA), and spectral-domain optical coherence 
      tomography (SD-OCT), and to investigate whether the PHP score predicts the need 
      for reinjection. METHODS: Consecutive patients with newly diagnosed exudative AMD 
      underwent the PHP metamorphopsia test, BCVA, and SD-OCT at five time points after 
      initiation of ranibizumab therapy (0.05 mL/0.5 mg). At the third and sixth 
      months, reevaluation for additional injections was done. The relationships 
      between PHP, BCVA, and SD-OCT parameters over time as well as their ability to 
      predict the need for reinjection were examined. RESULTS: Analysis included 17 
      eyes (17 patients, 70% females; mean age, 83.2 years). The mean PHP 
      metamorphopsia test score improved from 25.6 +/- 41 (baseline) to 10.7 +/- 20.1 (P < 
      0.05) over 6 months, after a mean of 4.2 (+/-1.0) injections. Mean reduction in 
      SD-OCT parameters well reflected the functional improvements as evaluated by PHP 
      (Spearman correlation = 0.9, P < 0.05). Mean BCVA did not improve over 6 months 
      (0.6 vs. 0.58 logMAR), and neither correlated with SD-OCT morphologic changes 
      (Spearman correlation = 0.1, P > 0.05) nor with PHP functional changes (Spearman 
      correlation = 0.1, P > 0.05). The PHP predicted the need for reinjection with an 
      accuracy of 75% (sensitivity, 83 +/- 12%; specificity, 67 +/- 15%), whereas a 
      combination of all the measurements (PHP, BCVA, and SD-OCT) yielded an accuracy 
      of 87% (sensitivity, 83 +/- 12%; specificity, 90 +/- 10%). CONCLUSIONS: Improvement 
      in the metamorphopsia test score after intravitreal injections of ranibizumab, as 
      well as its ability to predict the need for retreatment, suggest that PHP may be 
      used to monitor response to anti-VEGF therapy in patients with exudative AMD.
FAU - Querques, Giuseppe
AU  - Querques G
AD  - Department of Ophthalmology, University of Paris XII, Centre Hospitalier 
      Intercommunal de Creteil, Creteil, France. giuseppe.querques@hotmail.it
FAU - Querques, Lea
AU  - Querques L
FAU - Rafaeli, Omer
AU  - Rafaeli O
FAU - Canoui-Poitrine, Florence
AU  - Canoui-Poitrine F
FAU - Bandello, Francesco
AU  - Bandello F
FAU - Souied, Eric H
AU  - Souied EH
LA  - eng
PT  - Journal Article
DEP - 20110901
PL  - United States
TA  - Invest Ophthalmol Vis Sci
JT  - Investigative ophthalmology & visual science
JID - 7703701
RN  - 0 (Angiogenesis Inhibitors)
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - ZL1R02VT79 (Ranibizumab)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Angiogenesis Inhibitors/*therapeutic use
MH  - Antibodies, Monoclonal/*therapeutic use
MH  - Antibodies, Monoclonal, Humanized
MH  - Drug Monitoring
MH  - Exudates and Transudates
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Intravitreal Injections
MH  - Macular Degeneration/*diagnosis/drug therapy
MH  - Male
MH  - Prospective Studies
MH  - Ranibizumab
MH  - Reproducibility of Results
MH  - Retreatment
MH  - Sensitivity and Specificity
MH  - Tomography, Optical Coherence
MH  - Vision Disorders/*diagnosis/drug therapy
MH  - Visual Acuity/*physiology
MH  - Visual Field Tests/*instrumentation
MH  - Visual Fields/*physiology
EDAT- 2011/09/03 06:00
MHDA- 2011/10/27 06:00
CRDT- 2011/09/03 06:00
PHST- 2011/09/03 06:00 [entrez]
PHST- 2011/09/03 06:00 [pubmed]
PHST- 2011/10/27 06:00 [medline]
AID - 52/9/7012 [pii]
AID - 10.1167/iovs.11-7517 [doi]
PST - epublish
SO  - Invest Ophthalmol Vis Sci. 2011 Sep 1;52(9):7012-8. doi: 10.1167/iovs.11-7517.